期刊文献+

非布司他合成工艺改进 被引量:2

Improved Synthesis of Febuxostat
原文传递
导出
摘要 本研究对非布司他的合成工艺进行改进。邻羟基苯甲腈(2)与溴代异丁烷反应后,与N-溴代琥珀酰亚胺在室温条件下反应6 h得2-异丁氧基-5-溴苯甲腈(4),收率由文献的75.7%提升至95.3%。4与联硼酸频那醇酯经Miyaura硼基化反应得3-氰基-4-异丁氧基苯硼酸频那醇酯,与2-溴-4-甲基噻唑-5-甲酸乙酯在二噁烷/水的混合溶剂中经Suzuki反应得2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸乙酯,避免了有毒溶剂甲苯的使用,收率也由文献的65.4%提高至72.6%。最后再经水解得目标产物,总收率58.7%(以2计)。 In this study, the synthetic process of febuxostat was improved. 5-Bromo-2-isobutoxybenzonitrile(4) was obtained via a substitution of 2-hydroxybenzonitrile(2) and bromoisobutan, followed by bromination with N-bromosuccinimide at room temperature, the yield was increased from 75.7% to 95.3%. Then compound 4 reacted with bis(pinacolato)diboron via Miyaura borylation to give 3-cyano-4-isobutoxyphenylboronic acid pinacol ester. Then the latter was subjected to Suzuki coupling with ethyl 2-bromo-4-methylthiazole-5-carboxylate in dioxane/H_2 O to afford ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate with a yield of 72.6%, which was followed by a hydrolysis with sodium hydroxide to product the target compound with a total yield of 58.7%(based on 2).
作者 周世宇 李敏勇 ZHOU Shiyu;LI Minyong(Dept.of Medicinal Chemistry,School of Pharmacy,Shandong University,Jinan 250012)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2018年第9期1248-1251,共4页 Chinese Journal of Pharmaceuticals
关键词 非布司他 抗痛风药 选择性黄嘌呤氧化酶抑制剂 溴代 SUZUKI偶联 febuxostat anti-gout drug selective xanthine oxidase inhibitor bromination Suzuki coupling
  • 相关文献

参考文献4

二级参考文献42

  • 1YAMAMOTO T. Development of antihyperuricemic candidates[J]. Nippon Rinsho, 2003, 61 ( S1 ) : 209 - 212.
  • 2TAKANO Y, HASE-AOKI K, HORIUCHI H, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxldase/xanthine dehydyogenase[J]. Life Sci, 2005, 76(16) : 1835 - 1847.
  • 3BECKER M A, SCHUMACHER H R Jr, WORTMANN R L. Febuxostat compared with aUopurinol in patients with hyperurlcemia and gout [ J ]. N Engl J IVied, 2005, 353(23) :2450 - 2461.
  • 4BECKER M A, SCHUMACHER H R Jr, WORTMANN R L. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a 28-day, multicenter, phase Ⅱ, randomized, double-blind, placebo controlled dose-response clinical trial examining safety and efficacy in patients with gout [ J ]. Arthritis Rheum, 2005, 52(3) :916 - 923.
  • 5POHAR S, MURPHY G. Febuxostat for prevention of gout attacks [ J ]. Issues Emerg Health Technol, 2006, 87(8) : 1 - 4.
  • 6TAYLOR W :j, SCHUMACHER H R :Jr. Assessment of outcome in clinical trials of gout-a review of current measures [ :J ]. Rheumatology, 2007, 46 ( 12 ) : 1751 - 1756.
  • 7BRYAN T, EMMERSON M D. The treatment of gout[J]. Drug Ther, 1996, 334(7) : 445 - 451.
  • 8VERGE J P, ROFFEY P. Antiprotozoal thiazoles. 2- (5-nitro-2-thienyl)-thiazoles[J] .J Med Chem, 1975, 18(8) :794.
  • 9HE H M, CUSHMAN M. A versatile synthesis of 2- methoxyestradiol, an endogenous metabolite of estradiol which inhibits tubulin polymerization by binding to the colchicine binding site [ J ]. Bioorg Med Chem Lett, 1994, 4 (14) : 1725 - 1728.
  • 10VILLEMIN D, LALAOUI M, BEN A. Microwave activation in organic synthesis: an efficient one-pot synthesis of nitriles from aldehydes [ J ]. Chem Ind (London), 1991,5(3) : 176.

共引文献33

同被引文献23

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部